Skip to main content

Genizon Partners with NDEI to Continue Schizophrenia Studies with Quebec Founder Population

NEW YORK (GenomeWeb News) - Genizon Biosciences said today it has partnered with the Canadian company Neuropsychiatrie, Decouverte & Innovation to conduct further genome-wide research on schizophrenia-related genes Genizon has discovered.
Earlier this year, Genizon identified multiple genes associated with schizophrenia in a genome-wide association study using DNA samples from patients from the Quebec Founder Population.
Under the agreement with NDEI, the company will provide Genizon with a second set of samples from the Quebec Founder Population that it will use for further research.
NDEI was founded in 2002 as a spinoff company of the Centre de Recherche Universite Laval Robert-Giffard.
“We expect the results of these studies to lead to a new generation of safer and more effective treatments tailored to individual schizophrenia patients,” said Michel Maziade, a scientist at the University of Laval, which will provide access to the samples.
Financial terms of the agreement were not released.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.